Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Use all oral and topical medications as prescribed to promote healing
The GLP-1 foundation (shared) Both survodutide and tirzepatide leverage GLP-1 receptor agonism for: Central appetite suppression through hypothalamic signaling Delayed gastric emptying, which prolongs satiety Enhanced insulin secretion in response to meals Improved glucose homeostasis These shared effects explain why both drugs produce meaningful weight loss and glycemic improvement
The medication's long half-life means that missing a single dose typically does not result in immediate loss of glycemic control or weight management benefits, though consistent adherence remains important for optimal outcomes
* EBITDA margin expanded 500bp YoY to 29.4% (our estimate: 25.3%)
US$ 26.10
US$ 25.46
US$ 21.56
US$ 29.59
US$ 29.88
US$ 27.11
US$ 25.39
